1. Home
  2. RCMT vs TLSA Comparison

RCMT vs TLSA Comparison

Compare RCMT & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RCM Technologies Inc.

RCMT

RCM Technologies Inc.

HOLD

Current Price

$29.74

Market Cap

196.0M

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.29

Market Cap

161.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCMT
TLSA
Founded
1971
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
196.0M
161.6M
IPO Year
1997
2017

Fundamental Metrics

Financial Performance
Metric
RCMT
TLSA
Price
$29.74
$1.29
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$36.00
N/A
AVG Volume (30 Days)
67.1K
170.5K
Earning Date
04-03-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
27.38
N/A
EPS
2.14
N/A
Revenue
$186,737,000.00
N/A
Revenue This Year
$8.37
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.33
N/A
Revenue Growth
5.83
N/A
52 Week Low
$15.29
$0.87
52 Week High
$29.31
$2.60

Technical Indicators

Market Signals
Indicator
RCMT
TLSA
Relative Strength Index (RSI) 80.79 50.73
Support Level $18.30 $1.24
Resistance Level N/A $1.60
Average True Range (ATR) 1.61 0.10
MACD 0.88 0.01
Stochastic Oscillator 96.74 62.50

Price Performance

Historical Comparison
RCMT
TLSA

About RCMT RCM Technologies Inc.

RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Share on Social Networks: